Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Epidemiology of Non-alcoholic Fatty Liver Disease in North America

Author(s): Tamoore Arshad, Pegah Golabi, Linda Henry and Zobair M. Younossi*

Volume 26, Issue 10, 2020

Page: [993 - 997] Pages: 5

DOI: 10.2174/1381612826666200303114934

Price: $65

conference banner
Abstract

Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most common cause of chronic liver disease worldwide. This is primarily driven by the global epidemic of obesity and diabetes as well as the aging of the general population. Most of the epidemiology data of NAFLD for North America are published from studies originating in the United States (U.S.). The overall prevalence of NAFLD in the U.S. is estimated to be 24%. Hispanic Americans have a higher prevalence of NAFLD, whereas African Americans have a lower prevalence of NAFLD. The exact contributions of genetic and environmental factors on these differences in the prevalence rates have not been determined. From the spectrum of NAFLD, patients with non-alcoholic steatohepatitis (NASH) are at the highest risk of progression to cirrhosis and hepatocellular carcinoma (HCC). The most recent data regarding the progression of NASH suggest a complex pattern of progression and regression of fibrosis. Factors influencing the progression and regression of NASH have not been fully described. More research is needed to better understand NAFLD in Mexico and Canada.

Keywords: NAFLD, NASH, cirrhosis, PNPLA3, metabolic syndrome, cardiovascular disease.

« Previous
[1]
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes 2016; 64:: 73-84.
[http://dx.doi.org/10.1002/hep.28431]
[2]
Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases 2018; 67:: 328-57.
[3]
Golabi P, Bush H, Stepanova M, Locklear CT, Jacobson IM, Mishra A, et al. Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis Data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016 1994; 97: e11518
[4]
Moore JX, Chaudhary N, Akinyemiju T. Metabolic Syndrome Prevalence by Race/Ethnicity and Sex in the United States, National Health and Nutrition Examination Survey, 1988-2012. Prev Chronic Dis 2017; 16: E24
[5]
Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention 2018; 15:: 11-20.
[http://dx.doi.org/10.1038/nrgastro.2017.109]
[6]
Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World 2016; 20: 205-14.
[7]
Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease 2016; 65 : 10-7.
[http://dx.doi.org/10.1016/j.metabol.2016.01.012]
[8]
Bellentani S. The epidemiology of non-alcoholic fatty liver disease 2017; 37(Suppl 1): 81-4.
[http://dx.doi.org/10.1111/liv.13299]
[9]
Arshad T, Golabi P, Paik J, Mishra A, Younossi ZM. Prevalence of Nonalcoholic Fatty Liver Disease in the Female Population 2019; 3: 74-83.
[10]
Golabi P, Paik J, Reddy R, Bugianesi E, Trimble G, Younossi ZM. Prevalence and long-term outcomes of non-alcoholic fatty liver disease among elderly individuals from the United States 2019. 19:56
[http://dx.doi.org/10.1186/s12876-019-0972-6]
[11]
Bernal-Reyes R, Castro-Narro G, Malé-Velázquez R, Carmona-Sánchez R, González-Huezo MS, García-Juárez I, et al. The Mexican consensus on nonalcoholic fatty liver disease 2019; 84 : 69-99.
[http://dx.doi.org/10.1016/j.rgmxen.2019.02.003]
[12]
Martínez SGM, Flores A, Torre AG. Estudio epidemiológico de la enfermedad por hígado graso en población mexicana 2017; 17-21.
[13]
Lizardi-Cervera J, Laparra IB, Chavez-Tapia NC, Ramos Ostos ME, Uribe Esquivel M. Prevalencia de higado graso no alcoholico y sindrome metabolico en poblacion asintomatica 2006; 71 : 453-9.
[14]
Wells MM, Li Z, Addeman B, et al. Computed Tomography Measurement of Hepatic Steatosis: Prevalence of Hepatic Steatosis in a Canadian Population. Can J Gastroenterol Hepatol 2016; 20164930987
[http://dx.doi.org/10.1155/2016/4930987] [PMID: 27446844]
[15]
Sherman M, Bilodeau M, Cooper C, Mackie D, Depew W, Villeneuve J-P. Liver Disease in Canada [homepage on the Internet]. Canadian Liver Foundation 2013.Available from:. https://www.liver.ca/wpcontent/uploads/2017/09/CLF_LiverDiseaseInCanada_Synopsis_E.pdf
[16]
Allen AM, Therneau TM, Larson JJ, Coward A, Somers VK, Kamath PS. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study 2018; 67 : 1726-36.
[http://dx.doi.org/10.1002/hep.29546]
[17]
Younossi ZM, Golabi P, de Avila L, Minhui Paik J, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol 2019; 71(4): 793-801.
[http://dx.doi.org/10.1016/j.jhep.2019.06.021]
[18]
Fleischman MW, Budoff M, Zeb I, Li D, Foster T. NAFLD prevalence differs among hispanic subgroups: the Multi-Ethnic Study of Atherosclerosis 2014; 20 : 4987-93.
[http://dx.doi.org/10.3748/wjg.v20.i17.4987]
[19]
Patel YA, Gifford EJ, Glass LM, McNeil R, Turner MJ, Han B, et al. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration 2018; 47 : 268-78.
[http://dx.doi.org/10.1111/apt.14411]
[20]
Chinchilla-López P, Ramírez-Pérez O, Cruz-Ramón V, Canizales-Quinteros S, Domínguez-López A, Ponciano-Rodríguez G, et al. More Evidence for the Genetic Susceptibility of Mexican Population to Nonalcoholic Fatty Liver Disease through PNPLA3 2018; 17 : 250-5.
[http://dx.doi.org/10.5604/01.3001.0010.8644]
[21]
Martínez LA, Larrieta E, Kershenobich D, Torre A. The Expression of PNPLA3 Polymorphism could be the Key for Severe Liver Disease in NAFLD in Hispanic Population 2017; 16 : 909-15.
[http://dx.doi.org/10.5604/01.3001.0010.5282]
[22]
Saab S, Manne V, Nieto J, Schwimmer JB, Chalasani NP. Nonalcoholic Fatty Liver Disease in Latinos 2016; 14(5-12): e9-10.
[http://dx.doi.org/10.1016/j.cgh.2015.05.001]
[23]
Cantoral A, Contreras-Manzano A, Luna-Villa L, Batis C, Roldán-Valadez EA, Ettinger AS, et al. Dietary Sources of Fructose and Its Association with Fatty Liver in Mexican Young Adults. Nutrients 2019; 11(3) : pii; E522
[http://dx.doi.org/10.3390/nu11030522]
[24]
Balakrishnan M, Kanwal F, El-Serag HB, Thrift AP. Acculturation and Nonalcoholic Fatty Liver Disease Risk Among Hispanics of Mexican Origin: Findings From the National Health and Nutrition Examination Survey. Clin Gastroenterol Hepatol 2017; 15(2): 310-2.
[http://dx.doi.org/10.1016/j.cgh.2016.09.149] [PMID: 27712983]
[25]
López-Velázquez JA, Silva-Vidal KV, Ponciano-Rodríguez G, Chávez-Tapia NC, Arrese M, Uribe M, et al. The prevalence of nonalcoholic fatty liver disease in the Americas 2014; 13 : 166-78.
[http://dx.doi.org/10.1016/S1665-2681(19)30879-8]
[26]
Golabi P, Paik J, Hwang JP, Wang S, Lee HM, Younossi ZM. Prevalence and outcomes of non-alcoholic fatty liver disease (NAFLD) among Asian American adults in the United States. Liver Int 2019; 39(4): 748-57.
[27]
Uhanova J, Minuk G, Lopez Ficher F, Chandok N. Nonalcoholic Fatty Liver Disease in Canadian First Nations and Non-First Nations Patients. Canadian J Hep 2016; 2016: 6420408
[28]
Le MH, Devaki P, Ha NB, Jun DW, Te HS, Cheung RC, et al. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States 2017; 12 e0173499
[http://dx.doi.org/10.1371/journal.pone.0173499]
[29]
Diehl AM, Day C. Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis 2017; 377: 2063-72.
[30]
Massoud O, Charlton M. Nonalcoholic Fatty Liver Disease/ Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma 2018; 22 : 201-11.
[31]
Kabbany MN, Conjeevaram Selvakumar PK, Watt K, et al. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data. Am J Gastroenterol 2017; 112(4): 581-7.
[http://dx.doi.org/10.1038/ajg.2017.5] [PMID: 28195177]
[32]
White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review 2012; 10 : 1342-59.: e2
[http://dx.doi.org/10.1016/j.cgh.2012.10.001]
[33]
Mittal S, El-Serag HB, Sada YH, Kanwal F, Duan Z, Temple S, et al. Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease 2016; 14 : 124-31.: e1
[http://dx.doi.org/10.1016/j.cgh.2015.07.019]
[34]
Kanwal F, Kramer JR, Mapakshi S, Natarajan Y, Chayanupatkul M, Richardson PA, et al. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology 2018; 155(6): 1828-1837.e2.
[http://dx.doi.org/10.1053/j.gastro.2018.08.024]
[35]
Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009 2015; 62 : 1723-30.
[36]
Rodriguez-Hernandez H, Cervantes-Huerta M, Gonzalez JL, Marquez-Ramirez MD, Rodriguez-Moran M, Guerrero-Romero F. Nonalcoholic fatty liver disease in asymptomatic obese women 2010; 9 : 144-9.
[http://dx.doi.org/10.1016/S1665-2681(19)31652-7]
[37]
Golabi P, Otgonsuren M, de Avila L, Sayiner M, Rafiq N, Younossi ZM. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD) 2018; 97 e0214
[38]
Jinjuvadia R, Antaki F, Lohia P, Liangpunsakul S. Association Between Nonalcoholic Fatty Liver Disease and Metabolic Abnormalities in The United States Population 2017; 51: 160-6.
[39]
Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population 2012; 10 : 646-50.
[http://dx.doi.org/10.1016/j.cgh.2011.12.039]
[40]
Martínez-Alvarado MDR, Juárez-Rojas JG, Medina-Urrutia AX, Cardoso-Saldaña GC, González-Salazar MDC, Posadas-Sánchez R, et al. Association of fatty liver with cardiovascular risk factors and subclinical atherosclerosis in a Mexican population 2014; 66 : 407-14.
[41]
Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis 2017; 65 : 1557-65.
[42]
Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease 2018; 67 : 123-33.
[http://dx.doi.org/10.1002/hep.29466]
[43]
Younossi ZM, Loomba R, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, et al. Current and Future Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH). Hepatology 2018; 68(1): 361-71.
[44]
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO) EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. 2016; 64 : 1388-402.
[45]
Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis 2010; 362 : 1675-85.
[http://dx.doi.org/10.1056/NEJMoa0907929]
[46]
Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial 2011; 305 : 1659-68.
[http://dx.doi.org/10.1001/jama.2011.520]
[47]
He L, Liu X, Wang L, Yang Z. Thiazolidinediones for nonalcoholic steatohepatitis: A meta-analysis of randomized clinical trials 2016. 95: e4947
[http://dx.doi.org/10.1097/MD.0000000000004947]
[48]
Grygiel-Górniak B. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review 2014; 13:: 17.
[49]
Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial 2015; 385 : 956-65.
[50]
Ganesan LP, Mates JM, Cheplowitz AM, Avila CL, Zimmerer JM, Yao Z, et al. Scavenger receptor B1, the HDL receptor, is expressed abundantly in liver sinusoidal endothelial cells 2016. 6: 20646.
[http://dx.doi.org/10.1038/srep20646]
[51]
Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial 2019; 394 : 2184-96.
[http://dx.doi.org/10.1016/S0140-6736(19)33041-7]

Rights & Permissions Print Cite
Article Metrics
222
16
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy